Literature DB >> 22372219

Cavitating pulmonary tuberculosis: a global challenge.

Waseem Saeed1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22372219      PMCID： PMC4953415          DOI： 10.7861/clinmedicine.12-1-40

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


× No keyword cloud information.
  9 in total

Review 1.  Immunology of tuberculosis.

Authors:  J L Flynn; J Chan
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  Malignant tuberculosis.

Authors:  Brig Waseem Saeed
Journal:  J Ayub Med Coll Abbottabad       Date:  2006 Jul-Sep

3.  Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis.

Authors:  Moises Palaci; Reynaldo Dietze; David Jamil Hadad; Fabiola Karla Corrêa Ribeiro; Renata Lyrio Peres; Solange Alves Vinhas; Ethel Leonor Noia Maciel; Valdério do Valle Dettoni; Libby Horter; W Henry Boom; John L Johnson; Kathleen D Eisenach
Journal:  J Clin Microbiol       Date:  2007-10-10       Impact factor: 5.948

4.  Retrospective audit of patients treated for MDR-TB in re-treatment category.

Authors:  Waseem Saeed; Arshad Naseem; Jamal Ahmed
Journal:  J Ayub Med Coll Abbottabad       Date:  2009 Apr-Jun

5.  Post-tuberculous chronic obstructive pulmonary disease.

Authors:  Inam Muhammad Baig; Waseem Saeed; Kanwal Fatima Khalil
Journal:  J Coll Physicians Surg Pak       Date:  2010-08       Impact factor: 0.711

6.  Evidence based medicine: what it is and what it isn't.

Authors:  D L Sackett; W M Rosenberg; J A Gray; R B Haynes; W S Richardson
Journal:  BMJ       Date:  1996-01-13

7.  Short-course (6-month) cooperative tuberculosis study in Poland: results 30 months after completion of treatment.

Authors:  M Zierski; E Bek; M W Long; D E Snider
Journal:  Am Rev Respir Dis       Date:  1981-09

Review 8.  Tuberculosis therapy: past, present and future.

Authors:  M D Iseman
Journal:  Eur Respir J Suppl       Date:  2002-07

9.  Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.

Authors:  Debra Benator; Mondira Bhattacharya; Lorna Bozeman; William Burman; Antonino Cantazaro; Richard Chaisson; Fred Gordin; C Robert Horsburgh; James Horton; Awal Khan; Christopher Lahart; Beverly Metchock; Constance Pachucki; Llewellyn Stanton; Andrew Vernon; M Elsa Villarino; Yong Chen Wang; Marc Weiner; Stephen Weis
Journal:  Lancet       Date:  2002-08-17       Impact factor: 79.321
  9 in total
  4 in total

1.  Boarding issue in a commercial flight for patients with cavitary pulmonary tuberculosis: A case report.

Authors:  Woori Jo; Chuiyong Pak; Yangjin Jegal; Kwang Won Seo
Journal:  World J Clin Cases       Date:  2020-02-06       Impact factor: 1.337

2.  Humanized Mouse Model Mimicking Pathology of Human Tuberculosis for in vivo Evaluation of Drug Regimens.

Authors:  Frida Arrey; Delia Löwe; Stefanie Kuhlmann; Peggy Kaiser; Pedro Moura-Alves; Gopinath Krishnamoorthy; Laura Lozza; Jeroen Maertzdorf; Tatsiana Skrahina; Alena Skrahina; Martin Gengenbacher; Geraldine Nouailles; Stefan H E Kaufmann
Journal:  Front Immunol       Date:  2019-01-31       Impact factor: 7.561

3.  Delay in diagnosis of pulmonary tuberculosis increases the risk of pulmonary cavitation in pastoralist setting of Ethiopia.

Authors:  Fentabil Getnet; Meaza Demissie; Alemayehu Worku; Tesfaye Gobena; Rea Tschopp; Michael Girmachew; Gebeyehu Assefa; Berhanu Seyoum
Journal:  BMC Pulm Med       Date:  2019-11-06       Impact factor: 3.317

4.  Explorative Analysis of Treatment Outcomes of Levofloxacin- and Moxifloxacin-Based Regimens and Outcome Predictors in Ethiopian MDR-TB Patients: A Prospective Observational Cohort Study.

Authors:  Temesgen Sidamo; Workineh Shibeshi; Getnet Yimer; Eleni Aklillu; Ephrem Engidawork
Journal:  Infect Drug Resist       Date:  2021-12-18       Impact factor: 4.177
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.